

MosaiQ AiPlex[®] VAS

Autoimmune Vasculitis Microarray Solution

Autoimmune Vasculitis

Not available for diagnostic purposes in the US.
Subject to FDA clearance



Designed to provide comprehensive Autoimmune Vasculitis diagnostic insights and workflow efficiency

MPO

Combining multiple markers such as **anti-myeloperoxidase (MPO) and anti-proteinase 3 (PR3)** may help to diagnose the main **ANCA-Associated Vasculitis**, while optimizing lab workflow efficiencies.²⁻⁴

PR3

GBM

Anti-Glomerular Basement Membrane (GBM) antibodies are associated with Anti-GBM disease that can also be detected using MosaiQ[®].⁵

Autoimmune vasculitis (VAS) causes inflammation of blood vessel walls, potentially leading to organ and tissue damage. Affected vessel type (size), organ involvement and clinical symptoms depend on various types.

While its exact cause is often unknown, diagnosis can be difficult because it may present as a medical emergency and vasculitis can lead to life-threatening complications.

AliveDx **planar microarray supporting Autoimmune Vasculitis diagnosis, AiPlex VAS**, is designed to deliver rapid in-vitro test results, **helping to reduce the time to results for patients.**

The panel combines MPO, PR3 and GBM providing a comprehensive analysis in every sample as early diagnosis is crucial to prevent irreversible tissue damage and start appropriate treatment as soon as possible.¹⁻⁷

Fast, Easy, Comprehensive MosaiQ AiPlex® VAS



Contains key markers recommended by guidelines such as, European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis: 2022 update.⁵



Generates multiple insights in one report with only 10 µl patient sample. One microarray provides up to 3 individual results.



Reduces hands-on time and storage space with ready to use, concentrated onboard reagents and buffers.



Saves time while avoiding human errors with a standardized master curve embedded into RFID* tags, included with all reagents and microarrays.



Shares key reagents with other panels, enabling combined autoimmune diseases, allergy, and further testing.

* RFID: Radio Frequency Identification



The MosaiQ AiPlex VAS panel, run on the MosaiQ platform, is designed to help reduce time to results for patients with Autoimmune Vasculitis.



Simple Workflow

- Patients sample in, result out in one single step
- QC and calibration embedded



Fast Results

- Use STAT position to prioritize urgent samples
- One sample tube (low volume) for multiple tests



Actionable Insights

- Panels help streamline clinical decision-making for physicians
- Comprehensive panels simplify complex testing pathways

1 Treppo E et al. Systemic vasculitis: one year in review 2024. Clin Exp Rheumatol. 2024;42(4):771-781.
2 Robson JC et al. 2022 ACR/EULAR GPA Classification Criteria. Ann Rheum Dis. 2022;81(3):315-320.
3 Suppiah R et al. 2022 ACR/EULAR MPA Classification Criteria. Ann Rheum Dis. 2022;81(3):321-326.
4 Grayson PC et al. 2022 ACR/EULAR EGPA Classification Criteria. Ann Rheum Dis. 2022;81(3):309-314.
5 KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.

6 Ntatsaki E et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306-9.
7 Hellmich B et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30-47.



Find out more!

©AliveDx Suisse SA. 2025. The AliveDx logo, AliveDx, MosaiQ, MosaiQ AiPlex, MosaiQ AllergyPlex COMBO and LumiQ are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories. Subject to regulatory clearance. This product is not currently available in the USA, cleared or approved by the U.S. Food and Drug Administration (FDA) for clinical use.

AliveDx